Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
J Clin Psychiatry. 2007;68 Suppl 8:35-41.

Revisiting monoamine oxidase inhibitors.

Author information

  • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.

Abstract

Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.

PMID:
17640156
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Allen Press, Inc.
    Loading ...
    Write to the Help Desk